Category: Pharmaceuticals
-
![Medexus Pharmaceuticals (MDP.TO): A growing core business breaking company records]()
Medexus Pharmaceuticals (MDP.TO): A growing core business breaking company records
*originally published 01-16-23 Medexus Pharmaceuticals (MDP.TO) is a specialty pharma company. They are not biotech. There is no research and development here. Medexus is all about sales and marketing, bringing over drugs that are already licensed in Western Europe and then bringing them to North America. A very smart business model which has seen Medexus carve…
-
![Medexus Pharmaceuticals (MDP.TO) Q2 2023 revenue expected to exceed US$27 million]()
Medexus Pharmaceuticals (MDP.TO) Q2 2023 revenue expected to exceed US$27 million
Medexus Pharmaceuticals (MDP.TO) is a specialty pharma company that has been making big moves on the charts. The company is not a biotech company. They do not do research and development, but instead bring over drugs that are already licensed in Western Europe to North America which sees them carve out a nice and profitable…
-
![Medexus Pharmaceutical (MDP.T) readies for powerful year of growth in specialty pharma sector]()
Medexus Pharmaceutical (MDP.T) readies for powerful year of growth in specialty pharma sector
Big pharma firms like Abbvie can offer incredible product growth potential to investors, but they also saddle shareholders with tremendous risk in terms of regulatory approval and capital cost. According to a recent study which tracked the success rates of clinical drug development through to FDA approval between 2006-2015, just 9.6% of the drug candidates…
-
![Medexus (MDP.T) resubmits Treosulfan NDA to FDA]()
Medexus (MDP.T) resubmits Treosulfan NDA to FDA
Medexus (MDP.T), a Canadian-based specialty pharma firm focused on acquiring and distributing innovative rare disease treatment solutions in North America, announced today that its strategic partner, medac, had resubmitted its New Drug Application (NDA) for treosulfan to the U.S. Food and Drug Administration. This submission was a response to the FDA request to submit information…
-
![Revive Therapeutics (RVV.C) clears FDA hurdles]()
Revive Therapeutics (RVV.C) clears FDA hurdles
Last year Big Pharma unleashed 1,500 lobbyists to Washington, DC, who then cut cheques for $177 million to keep drug costs high. The lobbyists deserve bonuses. The average U.S. citizen spends $1,200 per year on prescription medicines, while people in other western countries spend an average of $550/year. Public health data indicates that the gluttony…
-
![ERYTECH Pharma (ERYP.Q) has a GRASPA® on ALL, shares up +70%]()
ERYTECH Pharma (ERYP.Q) has a GRASPA® on ALL, shares up +70%
A Need for Alternatives $54.898M Market Capitalization ERYTECH Pharma (ERYP.Q) announced today that the Company has sold its US manufacturing facility to Catalent, a leading contract development and manufacturing organization (CDMO) in advanced therapies. Under the terms of the agreement, Catalent has agreed to purchase ERYTECH’s US facility for a total consideration of $44.5 million. That’s…
-
![Filament Health (FH.NEO) is doing the work to stand out in the psychedelics sector]()
Filament Health (FH.NEO) is doing the work to stand out in the psychedelics sector
I’ll admit that I’m beginning to have my suspicions about the psychedelic sector. The question I’ve started asking when I look at a new psychedelics company is where’s the evidence that they’re actually serious about getting products on shelves? How many startup drug companies at will never see the inside of a laboratory? Why? The…
-
![Today’s Idea: Perimeter Medical Imaging AI (PINK.V) to Set New Standard for BCS]()
Today’s Idea: Perimeter Medical Imaging AI (PINK.V) to Set New Standard for BCS
I’ve said it before but I will say it again. Cancer is a bitch. In fact, this group of diseases is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, according to the World Health Organization (WHO). For starters, what the hell is cancer? Cancer arises from the transformation of…
-
![Today’s Idea: Valeo Pharma (VPH.C) Boasts an Impressive Portfolio and Achieves Significant Growth]()
Today’s Idea: Valeo Pharma (VPH.C) Boasts an Impressive Portfolio and Achieves Significant Growth
Even during my university days, I would find myself grasping my chest, wheezing after a short 15-minute walk to campus. In terms of fitness, I would consider myself to be above average. With this in mind, I found it startling that I was struggling to do something as trivial as walking to class. Drenched in…
-
![Mind Cure Health (MCUR.C): a hidden psychedelics gem – Today’s Idea]()
Mind Cure Health (MCUR.C): a hidden psychedelics gem – Today’s Idea
The World Health Organization (WHO) has listed depression as a leading cause of disability worldwide and a major contributor to the overall global burden of disease. Unfortunately, traditional treatments aren’t providing the sustainable answers we need, so companies like Mind Cure Health (MCUR.C) have integrated ancient therapeutics with modern modalities and technologies to effectively heal…
